



PRIOR AUTHORIZATION POLICY

- POLICY:** Psychiatry – Spravato Prior Authorization Policy
- Spravato® (esketamine nasal spray – Janssen)

REVIEW DATE: 04/24/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Spravato, a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, is indicated in conjunction with an oral antidepressant for the treatment of:¹

- Depressive symptoms in adults with **major depressive disorder (MDD) with acute suicidal ideation or behavior.**
- **Treatment-resistant depression (TRD)** in adults.

Limitation of Use: The effectiveness of Spravato in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of Spravato does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of Spravato. Spravato is not approved as an anesthetic agent. The safety and effectiveness of Spravato as an anesthetic agent have not been established.

Spravato should be administered in conjunction with an oral antidepressant.¹ For MDD with acute suicidal ideation or behavior, the recommended dosage is 84 mg twice weekly for 4 weeks. The dosage may be reduced to 56 mg twice weekly based on tolerability. After 4 weeks of treatment, evidence of therapeutic benefit should be evaluated to determine the need for continued treatment. The use of Spravato, in conjunction with an oral antidepressant, beyond 4 weeks has not been systematically evaluated in the treatment of depressive symptoms in patients with MDD with acute

suicidal ideation or behavior. For treatment-resistant depression, the recommended dose is 56 mg intranasally on Day 1, followed by 56 mg or 84 mg intranasally twice weekly for Weeks 1 to 4. On Weeks 5 to 8, Spravato should be administered once weekly at a dose of 56 mg or 84 mg intranasally. On Week 9 and thereafter, the dosing frequency should be individualized to the least frequent dosing to maintain remission/response (either every 2 weeks or once weekly) at a dose of 56 mg or 84 mg. Spravato must be administered under the direct supervision of a healthcare provider.

Disease Overview

Major depressive disorder is a serious, life-threatening condition with high rates of morbidity and a chronic disease course.² Major depressive disorder is considered the leading cause of disability worldwide and is also associated with increased mortality rates.^{3,4} About 30% to 40% of patients with major depressive disorder fail to respond to first-line treatments including oral antidepressant medications of all classes (e.g., selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants [TCAs], bupropion) and/or psychotherapy.^{2,5} In addition, the onset of treatment response for these modalities, even when effective, often takes ≥ 4 weeks, leading to greater suffering, expense, and risk. For regulatory purposes, the FDA considers patients to have treatment-resistant depression if they have MDD and they have not responded to treatment despite trials of at least two antidepressants given at adequate doses for an adequate duration in the current episode.²

The available treatments for treatment-resistant depression are limited.² Prior to the approval of Spravato, only one medication was FDA-approved for treatment-resistant depression, Symbyax[®] (olanzapine and fluoxetine capsules). Symbyax is indicated for treatment-resistant depression (major depressive disorder in patients who do not respond to two separate trials of different antidepressants of adequate dose and duration in the current episode) and acute depressive episodes in bipolar I disorder.⁶

Guidelines

In 2022, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) published a guideline for the management of MDD.⁷ The guideline divides treatment into uncomplicated MDD and MDD that is severe or has a partial or limited response to initial treatment. For uncomplicated MDD, the guideline recommends that MDD be treated with either psychotherapy (i.e., acceptance and commitment therapy, behavioral therapy/behavioral activation, cognitive behavioral therapy, interpersonal therapy, mindfulness-based cognitive therapy, problem-solving therapy, or short-term psychodynamic psychotherapy) or pharmacotherapy (i.e., bupropion, mirtazapine, selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], trazodone, vilazodone, or vortioxetine) as monotherapy, based on patient preference. Factors including treatment response, severity, and chronicity may lead to other treatment strategies, such as augmentation, combination treatment, switching of treatments, or use of non-first-line treatments. When choosing an initial pharmacotherapy, the guideline suggests against using esketamine, ketamine, monoamine oxidase inhibitors (MAOIs), nefazodone, or tricyclic antidepressants (TCAs). For the treatment of MDD

that is severe or has a partial or limited response to initial treatment, the guideline recommends offering a combination of pharmacotherapy and evidence-based psychotherapy for MDD characterized as severe (e.g., nine-item patient health questionnaire [PHQ-9] score > 20), persistent (duration > 2 years), or recurrent (\geq two episodes). For patients with MDD who have shown partial or no response to an adequate trial of initial pharmacotherapy, the guideline suggests switching to another antidepressant, switching to psychotherapy, augmenting with psychotherapy, or augmenting with a second-generation antipsychotic. For patients who have shown partial or no response to \geq two adequate pharmacologic treatment trials, the guideline suggests offering repetitive transcranial magnetic stimulation for treatment. For patients with MDD who have not responded to several adequate pharmacologic trials, the guideline suggests ketamine or esketamine for augmentation. For patients with MDD who achieve remission with antidepressants, the guideline recommends continuation of antidepressants at the therapeutic dose for \geq 6 months to decrease risk for relapse. For patients with MDD at high risk for relapse or recurrence (e.g., \geq two prior episodes, unstable remission status), the guideline suggests offering a course of cognitive behavioral therapy, interpersonal therapy, or mindfulness-based cognitive therapy during the continuation phase of treatment (i.e., after remission is achieved).

Abuse and Misuse

Spravato contains esketamine, a Schedule III controlled substance (CIII), which may be subject to abuse and diversion.¹ Assess each patient's risk for abuse or misuse prior to prescribing Spravato. All patients receiving Spravato should be monitored for the development of these behaviors or conditions, including drug-seeking behavior, while on therapy. Patients with a history of drug abuse or dependence are at greater risk. Careful consideration should be given prior to prescribing Spravato to individuals with a history of substance use disorder.

Safety

Spravato labeling includes a Boxed Warning regarding sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in pediatric and young adult patients.¹ The most common psychological effects of Spravato were dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization (61% to 84% of patients treated with Spravato developed dissociative or perceptual changes based on the Clinician-Administered Dissociative States Scale). Given its potential to induce dissociative effects, carefully assess patients with psychosis before administering Spravato; treatment should be initiated only if the benefit outweighs the risk.

Because of the risks of serious adverse outcomes resulting from sedation, dissociation, respiratory depression, and abuse and misuse, Spravato is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).¹ Healthcare settings must be certified in the program and ensure that Spravato is only dispensed in healthcare settings and administered to patients who are enrolled in the program, administered by patients under the direct observation of a healthcare provider, and that patients are monitored by a healthcare provider for at least 2 hours after administration of Spravato. Pharmacies must be

certified in the REMS and must only dispense Spravato to healthcare settings that are certified in the program.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Spravato. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Spravato as well as the monitoring required for adverse events and efficacy, approval requires Spravato to be prescribed by a physician who specializes in the condition being treated.

Note: A 2-month approval duration is applied for the indication of MDD with Acute Suicidal Ideation or Behavior to allow time for the scheduling and administration of a 4-week course of therapy at a certified healthcare setting. If after completing the 4-week course of therapy for MDD with Acute Suicidal Ideation or Behavior, another request for Spravato is submitted and the patient meets the approval criteria, then another 4-week course of treatment (with a 2-month approval duration to complete the course of therapy) could be approved.

• **Spravato® (esketamine nasal spray – Janssen)**
is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

1. Major Depressive Disorder with Acute Suicidal Ideation or Behavior.

Approve for 2 months if the patient meets ALL of the following (A, B, C, D, and E):

A) Patient is \geq 18 years of age; AND

B) Patient has major depressive disorder that is considered to be severe, according to the prescriber; AND

C) Patient is concomitantly receiving at least one oral antidepressant; AND

Note: Antidepressants may include, but are not limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), mirtazapine, and bupropion.

D) Patient has ONE of the following (i or ii):

i. No history of psychosis; OR

ii. History of psychosis and the prescriber believes that the benefits of Spravato outweigh the risks; AND

E) The medication is prescribed by a psychiatrist.

2. Treatment-Resistant Depression. Approve for 6 months if the patient meets ALL of the following (A, B, C, D, E, and F):

A) Patient is \geq 18 years of age; AND

B) Patient meets BOTH of the following (i and ii):

- i. Patient has demonstrated nonresponse ($\leq 25\%$ improvement in depression symptoms or scores) to at least two different antidepressants, each from a different pharmacologic class, according to the prescriber; AND
Note: Different pharmacologic classes of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), bupropion, mirtazapine, etc.
- ii. Each antidepressant was used at therapeutic dosages for at least 6 weeks in the current episode of depression, according to the prescriber; AND
- C) Patient is concomitantly receiving at least one oral antidepressant; AND
Note: Antidepressants may include, but are not limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), mirtazapine, and bupropion.
- D) Patient has ONE of the following (i or ii):
 - i. No history of psychosis; OR
 - ii. History of psychosis and the prescriber believes that the benefits of Spravato outweigh the risks; AND
- E) The patient's history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP), according to the prescriber; AND
- F) The medication is prescribed by a psychiatrist.

CONDITIONS NOT COVERED

- **Spravato® (esketamine nasal spray – Janssen) is(are) considered experimental, investigational or unproven for ANY other use(s); criteria will be updated as new published data are available.**

REFERENCES

1. Spravato® nasal spray [prescribing information]. Titusville, NJ: Janssen; October 2023.
2. FDA news release. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. March 5, 2019. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified>. Accessed on April 22, 2024.
3. National Institute of Mental Health. Major Depression. Last updated: July 2023. Available at: <https://www.nimh.nih.gov/health/statistics/major-depression.shtml>. Accessed on April 22, 2024.
4. World Health Organization. Depressive disorder (depression). Available at: Depressive disorder (depression) (who.int) . Accessed on April 22, 2024.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006;163(11):1905-17.
6. Symbyax® capsules [prescribing information]. Indianapolis, IN: Lilly; August 2023.
7. McQuaid JR, Buelt A, Capaldi V, et al. The management of major depressive disorder: synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. *Ann Intern Med*. 2022;175(10):1440-1451.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Treatment-Resistant Depression: Removed "unless unavailable in the state" from criterion requiring the "patient's history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP)." Removed Note regarding Missouri not having a statewide PDMP (legislation was enacted in 2021).	04/19/2023
Update	06/01/2023: Policy Statement: A Note was added to the Policy Statement to clarify that a 2-month approval duration is applied for the indication of MDD with Acute Suicidal Ideation or Behavior to allow time for the scheduling and administration of a 4-week course of therapy at a certified healthcare setting. Additionally, if after completing the 4-week course of therapy for MDD with Acute Suicidal Ideation or Behavior, another request for Spravato is submitted and the patient meets the approval criteria, then another 4-week course of treatment (with a 2-month approval duration to complete the course of therapy) could be approved.	--
Annual Revision	No criteria changes.	04/24/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.